These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15867872)

  • 1. COX-2-selective inhibitor valdecoxib induces severe allergic skin reactions.
    Talhari C; Lauceviciute I; Enderlein E; Ruzicka T; Homey B
    J Allergy Clin Immunol; 2005 May; 115(5):1089-90. PubMed ID: 15867872
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)].
    Boehncke S; Boehncke WH
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2249-52. PubMed ID: 16208597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious dermatologic reaction associated with valdecoxib: report of two cases.
    Knowles SR; Phillips EJ; Wong G; Shear NH
    J Am Acad Dermatol; 2004 Dec; 51(6):1028-9. PubMed ID: 15583610
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular toxicity of valdecoxib.
    Ray WA; Griffin MR; Stein CM
    N Engl J Med; 2004 Dec; 351(26):2767. PubMed ID: 15608086
    [No Abstract]   [Full Text] [Related]  

  • 6. Parecoxib, valdecoxib, and cardiovascular risk.
    Furberg CD; Psaty BM; FitzGerald GA
    Circulation; 2005 Jan; 111(3):249. PubMed ID: 15655125
    [No Abstract]   [Full Text] [Related]  

  • 7. Valdecoxib: cutaneous and vascular risks.
    Prescrire Int; 2005 Apr; 14(76):63. PubMed ID: 15877326
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 9. Valdecoxib-associated acute generalized exanthematous pustulosis.
    Byerly FL; Nelson KC; Granko RP; Morrell DS; Cairns BA
    Burns; 2005 May; 31(3):383-7. PubMed ID: 15774300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
    Schug SA; Joshi GP; Camu F; Pan S; Cheung R
    Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New warnings for Bextra.
    FDA Consum; 2003; 37(1):5. PubMed ID: 12625292
    [No Abstract]   [Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX; Lee KY; Bertram CT; Goldstein JL
    Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of cystoid macular edema with valdecoxib.
    Reis A; Birnbaum F; Hansen LL; Reinhard T
    J Cataract Refract Surg; 2007 Apr; 33(4):682-5. PubMed ID: 17397743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valdecoxib-induced systemic contact dermatitis confirmed by positive patch test.
    Jaeger C; Jappe U
    Contact Dermatitis; 2005 Jan; 52(1):47-8. PubMed ID: 15701133
    [No Abstract]   [Full Text] [Related]  

  • 16. Exacerbation of carpal tunnel syndrome under treatment with valdecoxib.
    Ruppen W; Schüpfer GK
    Anesth Analg; 2005 Apr; 100(4):1215-1216. PubMed ID: 15781551
    [No Abstract]   [Full Text] [Related]  

  • 17. Could Bextra increase heart risks too?
    Health News; 2004 Dec; 10(12):2. PubMed ID: 15645556
    [No Abstract]   [Full Text] [Related]  

  • 18. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
    Mühlfeld AS; Floege J
    Clin Nephrol; 2005 Mar; 63(3):221-4. PubMed ID: 15786824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rapid and safe pain management. Promising new cyclooxygenase inhibitor].
    MMW Fortschr Med; 2002 Jul; 144(29-30):53. PubMed ID: 12219614
    [No Abstract]   [Full Text] [Related]  

  • 20. Valdecoxib : the rise and fall of a COX-2 inhibitor.
    Atukorala I; Hunter DJ
    Expert Opin Pharmacother; 2013 Jun; 14(8):1077-86. PubMed ID: 23517091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.